In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cerus Corporation

http://cerus.com/

Latest From Cerus Corporation

First Wave To Merge With ImmunogenX With Focus On Celiac Disease

Troubled by recent clinical disappointments, First Wave will combine with ImmunogenX to focus on that company’s Phase III-ready enzyme replacement therapy for celiac disease. A deep-pocketed partner waits in the wings.

M & A Business Strategies

Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds

Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.

Financing Innovation

Stock Watch: The Rise Of Biotech Platforms

In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.

Stock Watch Platform Technologies

First Wave Rises With Sanofi GI Deal

First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.

Deals Gastrointestinal
See All

Company Information

  • Industry
  • Medical Devices
    • Infection Control-Sterilization
UsernamePublicRestriction

Register